6.5899
price down icon0.27%   -0.0599
 
loading
Schlusskurs vom Vortag:
$6.53
Offen:
$6.48
24-Stunden-Volumen:
84,280
Relative Volume:
0.43
Marktkapitalisierung:
$14.51M
Einnahmen:
$895.50K
Nettoeinkommen (Verlust:
$-26.30M
KGV:
-4.0182
EPS:
-1.64
Netto-Cashflow:
$-23.84M
1W Leistung:
-12.11%
1M Leistung:
+23.11%
6M Leistung:
-48.32%
1J Leistung:
-84.04%
1-Tages-Spanne:
Value
$6.1101
$6.66
1-Wochen-Bereich:
Value
$5.95
$8.1639
52-Wochen-Spanne:
Value
$3.65
$45.60

Mainz Biomed N V Stock (MYNZ) Company Profile

Name
Firmenname
Mainz Biomed N V
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
71
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
MYNZ's Discussions on Twitter

Vergleichen Sie MYNZ mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
MYNZ
Mainz Biomed N V
6.60 14.51M 895.50K -26.30M -23.84M -1.64
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
533.94 203.73B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
205.79 146.40B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
A
Agilent Technologies Inc
136.43 38.93B 6.51B 1.29B 1.37B 4.42
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
455.65 37.65B 3.90B 887.87M 808.08M 10.67
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
198.26 34.52B 15.41B 1.37B 2.11B 7.50

Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-25 Herabstufung H.C. Wainwright Buy → Neutral
2023-11-21 Herabstufung Cantor Fitzgerald Overweight → Neutral
2022-06-21 Eingeleitet H.C. Wainwright Buy

Mainz Biomed N V Aktie (MYNZ) Neueste Nachrichten

pulisher
Feb 13, 2025

How To Trade (MYNZ) - Stock Traders Daily

Feb 13, 2025
pulisher
Feb 11, 2025

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire

Feb 11, 2025
pulisher
Feb 11, 2025

Mainz Biomed Collaborates with GANZIMMUN Diagnostics to Launch Enhanced ColoAlert Colorectal Cancer Screening Test in Germany - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

Mainz Biomed's Revolutionary DNA Tech Powers New German Cancer ScreeningWhat Sets It Apart - StockTitan

Feb 11, 2025
pulisher
Feb 06, 2025

A stock that deserves closer examination: Mainz Biomed N.V (MYNZ) - US Post News

Feb 06, 2025
pulisher
Feb 04, 2025

The Future of Mainz Biomed N.V: Analyzing MYNZ - The InvestChronicle

Feb 04, 2025
pulisher
Jan 28, 2025

Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Canada

Jan 28, 2025
pulisher
Jan 27, 2025

Mainz Biomed regains Nasdaq compliance with equity rule - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks

Jan 27, 2025
pulisher
Jan 27, 2025

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire

Jan 27, 2025
pulisher
Jan 27, 2025

Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan

Jan 27, 2025
pulisher
Jan 24, 2025

Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World

Jan 24, 2025
pulisher
Jan 21, 2025

Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire

Jan 21, 2025
pulisher
Jan 21, 2025

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian

Jan 21, 2025
pulisher
Jan 21, 2025

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com

Jan 21, 2025
pulisher
Jan 14, 2025

Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks

Jan 14, 2025
pulisher
Jan 02, 2025

Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World

Jan 02, 2025
pulisher
Dec 21, 2024

MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Dec 21, 2024
pulisher
Dec 20, 2024

Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com

Dec 20, 2024
pulisher
Dec 20, 2024

Mainz Biomed Partners with Quest Diagnostics to Advance Colorectal Cancer Screening in the U.S. - Citybuzz

Dec 20, 2024
pulisher
Dec 20, 2024

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq

Dec 20, 2024
pulisher
Dec 20, 2024

Mainz Biomed (MYNZ) Stock Soars In Pre-Hour Session On A New Partnership - Stocks Telegraph

Dec 20, 2024
pulisher
Dec 19, 2024

Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha

Dec 19, 2024
pulisher
Dec 19, 2024

Mainz Biomed partners with Quest for colorectal cancer test - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire

Dec 19, 2024
pulisher
Dec 19, 2024

Mainz Biomed Partners with Quest Diagnostics for Major Colorectal Cancer Screening Study - StockTitan

Dec 19, 2024
pulisher
Dec 18, 2024

Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline By Investing.com - Investing.com South Africa

Dec 18, 2024
pulisher
Dec 16, 2024

Mainz Biomed Secures $8 Million in Follow-On Offering - TipRanks

Dec 16, 2024
pulisher
Dec 16, 2024

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewswire

Dec 16, 2024
pulisher
Dec 16, 2024

Mainz Biomed Secures $8M Through Strategic Follow-on Offering with Dual-Warrant Structure - StockTitan

Dec 16, 2024
pulisher
Dec 14, 2024

Mainz Biomed prices $8M offering of shares and warrants - MSN

Dec 14, 2024
pulisher
Dec 13, 2024

Mainz Biomed Prices $8 Million Follow-On Offering to Boost Diagnostics Operations - TipRanks

Dec 13, 2024
pulisher
Dec 12, 2024

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - The Manila Times

Dec 12, 2024
pulisher
Dec 12, 2024

Mainz Biomed Announces $8M Follow-On Offering with Dual Warrant Structure - StockTitan

Dec 12, 2024
pulisher
Dec 11, 2024

Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma

Dec 11, 2024
pulisher
Dec 03, 2024

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga

Dec 03, 2024
pulisher
Dec 02, 2024

Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com India

Dec 02, 2024
pulisher
Dec 02, 2024

Mainz Biomed announces 1-for-40 reverse stock split - Medical Buyer

Dec 02, 2024
pulisher
Dec 01, 2024

Mainz Biomed (NASDAQ:MYNZ) Shares Set to Reverse Split on Tuesday, December 3rd - Defense World

Dec 01, 2024
pulisher
Nov 29, 2024

Mainz Biomed Announces Stock Split - GlobeNewswire

Nov 29, 2024
pulisher
Nov 29, 2024

Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues | MYNZ Stock News - StockTitan

Nov 29, 2024
pulisher
Nov 28, 2024

Q3 EPS Estimates for Mainz Biomed Increased by HC Wainwright - Defense World

Nov 28, 2024
pulisher
Nov 27, 2024

Mainz Biomed (NASDAQ:MYNZ) Rating Lowered to “Neutral” at HC Wainwright - Defense World

Nov 27, 2024
pulisher
Nov 25, 2024

What You Didn’t Know About Mainz Biomed N.V (NASDAQ: MYNZ) This Week - Stocks Register

Nov 25, 2024
pulisher
Nov 22, 2024

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test - Nasdaq

Nov 22, 2024
pulisher
Nov 19, 2024

Mainz Biomed and Thermo Fisher Scientific sign a collaboration agreement - Wiley

Nov 19, 2024

Finanzdaten der Mainz Biomed N V-Aktie (MYNZ)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
diagnostics_research DGX
$169.12
price up icon 0.24%
diagnostics_research LH
$246.76
price up icon 0.68%
$172.26
price up icon 0.94%
diagnostics_research WAT
$377.00
price down icon 0.49%
diagnostics_research MTD
$1,307.06
price up icon 0.65%
diagnostics_research IQV
$197.79
price up icon 0.89%
Kapitalisierung:     |  Volumen (24h):